RxDoctor Payments Data

Peter Gerges, MD

Hepatology · Orlando, FLNPI 1295364057

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Madrigal Pharmaceuticals at 28.1% of the total.

$1,032in general payments, 2019–2025

Across 30 payments — averaging $34.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$290
  • Mallinckrodt Hospital Products Inc.$177
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$139
  • Gilead$125
  • Boston Scientific$104
  • Intercept Pharmaceuticals, Inc.$87
  • plus $110 from 3 others

What the payments were for

  • Food & beverage$1,032100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$22,112
Medicare patients
79
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ursodiol12$682
Carvedilol21$167
Spironolactone16$146
Furosemide14$68

Paid to pharmacies, not to this prescriber.

Other hepatology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →